Abstract:Abstract Background Long non-coding RNAs (lncRNAs) are extensively intricate in the tumorigenesis and metastasis of various cancer types. Nevertheless, the detailed molecular mechanisms of lncRNA in non-small cell lung cancer (NSCLC) still remain mainly undetermined. Methods qPCR was performed to verify LINC00301 expression in NSCLC clinical specimens or cell lines. Fluorescence in situ hybridization (FISH) was conducted to identify the localization of LINC00301 in NSCLC cells. Chromatin immunoprecipitation (ChIP) was subjected to validate the binding activity between FOXC1 and LINC00301 promoters. RNA immunoprecipitation (RIP) was performed to explore the binding activity between LINC00301 and EZH2. RNA pull-down followed by dot-blot, protein domain mapping, and RNA electrophoresis mobility shift assay (EMSA) were conducted to identify the detailed binding regions between LINC00301 and EZH2. Alpha assay was conducted to quantitatively assess the interaction between LINC00301 and EZH2. Results LINC00301 is highly expressed in NSCLC and closely corelated to its prognosis by analyzing the relationship between differentially expressed lncRNAs and prognosis in NSCLC samples. in vitro and in vivo experiments revealed that LINC00301 facilitates cell proliferation, releases NSCLC cell cycle arrest, promotes cell migration and invasion, and suppresses cell apoptosis in NSCLC. In addition, LINC00301 increases regulatory T cell (Treg) while decreases CD8 + T cell population in LA-4/SLN-205-derived tumors through targeting TGF-β. The transcription factor FOXC1 mediates LINC00301 expression in NSCLC. Bioinformatics prediction and in vitro experiments indicated that LINC00301 (83–123 nucleotide [nt]) can directly bind to the enhancer of zeste homolog 2 (EZH2) (612–727 amino acid [aa]) to promote H3K27me3 at the ELL protein - associated factor 2 ( EAF2 ) promoter. EAF2 directly binds and stabilizes von Hippel–Lindau protein (pVHL), so downregulated EAF2 augments hypoxia-inducible factor 1 α (HIF1α) expression by regulating pVHL in NSCLC cells. Moreover, we also found that LINC00301 could function as a competing endogenous RNA (ceRNA) against miR-1276 to expedite HIF1α expression in the cytoplasm of NSCLC cells. Conclusions In summary, our present research revealed the oncogenic roles of LINC00301 in clinical specimens as well as cellular and animal experiments, illustrating the potential roles and mechanisms of the FOXC1/LINC00301/EZH2/EAF2/pVHL/HIF1α and FOXC1/LINC00301/miR-1276/HIF1α pathways, which provides novel insights and potential theraputic targets to NSCLC.

E2F1-Induced FTH1P3 Promoted Cell Viability and Glycolysis Through Mir-377-3p/ldha Axis in Laryngeal Squamous Cell Carcinoma

MicroRNA-145 Inhibits Growth of Laryngeal Squamous Cell Carcinoma by Targeting the PI3K/Akt Signaling Pathway.

LINC00319 promotes cancer stem cell-like properties in laryngeal squamous cell carcinoma via E2F1-mediated upregulation of HMGB3

HIF1A-dependent Overexpression of MTFP1 Promotes Lung Squamous Cell Carcinoma Development by Activating the Glycolysis Pathway

Reciprocal Regulation of Mir-1205 and E2F1 Modulates Progression of Laryngeal Squamous Cell Carcinoma.

Long non‑coding RNA ferritin heavy polypeptide 1 pseudogene 3 controls glioma cell proliferation and apoptosis via regulation of the microRNA‑224‑5p/tumor protein D52 axis.

MicroRNA-365a-3p Promotes Tumor Growth and Metastasis in Laryngeal Squamous Cell Carcinoma

MicroRNA-195-5p Suppresses the Proliferation, Migration, Invasion and Epithelial-Mesenchymal Transition of Laryngeal Cancer Cells in Vitro by Targeting E2F3

LncRNA FTH1P3: A New Biomarker for Cancer-Related Therapeutic Development

M6A reader YTHDF1 promotes malignant progression of laryngeal squamous carcinoma through activating the EMT pathway by EIF4A3

Long Non-Coding RNA FTH1P3 Facilitates Uveal Melanoma Cell Growth and Invasion Through Mir-224-5p

MiR-3682-3p promotes esophageal cancer progression by targeting FHL1 and activating the Wnt/β-catenin signaling pathway

Tmem161b-As1 Suppresses Proliferation, Invasion And Glycolysis By Targeting Mir-23a-3p/Hif1an Signal Axis In Oesophageal Squamous Cell Carcinoma

Mir-375 Suppresses IGF1R Expression and Contributes to Inhibition of Cell Progression in Laryngeal Squamous Cell Carcinoma

Elevated ITGA5 facilitates hyperactivated mTORC1-mediated progression of laryngeal squamous cell carcinoma via upregulation of EFNB2

FOXC1-mediated LINC00301 facilitates tumor progression and triggers an immune-suppressing microenvironment in non-small cell lung cancer by regulating the HIF1α pathway

E2F1 As a Potential Prognostic and Therapeutic Biomarker by Affecting Tumor Development and Immune Microenvironment in Hepatocellular Carcinoma.

LINC01554-Mediated Glucose Metabolism Reprogramming Suppresses Tumorigenicity in Hepatocellular Carcinoma via Downregulating PKM2 Expression and Inhibiting Akt/mTOR Signaling Pathway

Targeting SKA3 suppresses the proliferation and chemoresistance of laryngeal squamous cell carcinoma via impairing PLK1–AKT axis-mediated glycolysis

PFKL Promotes Cell Viability and Glycolysis and Inhibits Cisplatin Chemosensitivity of Laryngeal Squamous Cell Carcinoma

Fibrinogen Like Protein-1 Knockdown Suppresses the Proliferation and Metastasis of TU-686 Cells and Sensitizes Laryngeal Cancer to LAG-3 Blockade